The latest price target for Calumet (NASDAQ:CLMT) was reported by Goldman Sachs on April 30, 2025. The analyst firm set a price target for $14.00 expecting CLMT to rise to within 12 months (a possible 24.44% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Calumet (NASDAQ:CLMT) was provided by Goldman Sachs, and Calumet maintained their buy rating.

The last upgrade for Calumet Inc happened on March 17, 2025 when UBS raised their price target to $12. UBS previously had a sell for Calumet Inc.

The last downgrade for Calumet Inc happened on February 4, 2025 when UBS changed their price target from $20.5 to $15 for Calumet Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calumet, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calumet was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

While ratings are subjective and will change, the latest Calumet (CLMT) rating was a maintained with a price target of $16.00 to $14.00. The current price Calumet (CLMT) is trading at is $11.25, which is out of the analyst’s predicted range.